New data at ddw 2025 further demonstrates the tissuecypher® test's ability to identify patients at increased risk for developing esophageal cancer

Additionally, an expert physician panel convened by endoscopynow will host a product theater on sunday, may 4, at 2:45 p.m. pacific time, titled, “the time is now: a clinical practice model to help prevent progression from barrett's to eac” friendswood, texas, may 02, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, will share new data on its tissuecypher barrett's esophagus test via two posters at the digestive disease week® (ddw 2025) annual meeting, being held may 3-6 in san diego.
CSTL Ratings Summary
CSTL Quant Ranking